Thu, August 17, 2023
Wed, August 16, 2023
Tue, August 15, 2023
Mon, August 14, 2023
Sun, August 13, 2023
Fri, August 11, 2023

Sumant Kulkarni Maintained (BTAI) at Strong Buy with Decreased Target to $20 on, Aug 15th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-20-on-aug-15th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Sumant Kulkarni of Canaccord Genuity, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $76 to $20 on, Aug 15th, 2023.

Sumant has made no other calls on BTAI in the last 4 months.



There are 2 other peers that have a rating on BTAI. Out of the 2 peers that are also analyzing BTAI, 1 agrees with Sumant's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, July 17th, 2023


This is the rating of the analyst that currently disagrees with Sumant


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $60 on, Monday, July 3rd, 2023

Publication Contributing Sources